Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
dc.rights.license | open | en_US |
dc.contributor.author | GHESQUIERES, Herve | |
dc.contributor.author | CHERBLANC, Fanny | |
dc.contributor.author | BELOT, Aurelien | |
dc.contributor.author | MICON, Sophie | |
dc.contributor.author | BOUABDALLAH, Krimo | |
dc.contributor.author | ESNAULT, Cyril | |
dc.contributor.author | FORNECKER, Luc-Matthieu | |
dc.contributor.author | THOKAGEVISTK, Katia | |
dc.contributor.author | BONJOUR, Maxime | |
dc.contributor.author | BIJOU, Fontanet | |
dc.contributor.author | HAIOUN, Corinne | |
dc.contributor.author | MORINEAU, Nadine | |
dc.contributor.author | YSEBAERT, Loic | |
dc.contributor.author | DAMAJ, Gandhi | |
dc.contributor.author | TESSOULIN, Benoit | |
dc.contributor.author | GUIDEZ, Stephanie | |
dc.contributor.author | MORSCHHAUSER, Franck | |
dc.contributor.author | THIEBLEMONT, Catherine | |
dc.contributor.author | CHAUCHET, Adrien | |
dc.contributor.author | GRESSIN, Remy | |
dc.contributor.author | JARDIN, Fabrice | |
dc.contributor.author | FRUCHART, Christophe | |
dc.contributor.author | LABOURE, Gaelle | |
dc.contributor.author | FOUILLET, Ludovic | |
dc.contributor.author | LIONNE-HUYGHE, Pauline | |
dc.contributor.author | BONNET, Antoine | |
dc.contributor.author | LEBRAS, Laure | |
dc.contributor.author | AMORIM, Sandy | |
dc.contributor.author | LEYRONNAS, Cecile | |
dc.contributor.author | OLIVIER, Gaelle | |
dc.contributor.author | GUIEZE, Romain | |
dc.contributor.author | HOUOT, Roch | |
dc.contributor.author | LAUNAY, Vincent | |
dc.contributor.author | DRENOU, Bernard | |
dc.contributor.author | FITOUSSI, Olivier | |
dc.contributor.author | DETOURMIGNIES, Laurence | |
dc.contributor.author | ABRAHAM, Julie | |
dc.contributor.author | SOUSSAIN, Carole | |
dc.contributor.author | LACHENAL, Florence | |
dc.contributor.author | PICA, Gian Matteo | |
dc.contributor.author | FOGARTY, Patrick | |
dc.contributor.author | CONY-MAKHOUL, Pascale | |
dc.contributor.author | BERNIER, Adeline | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | LE GUYADER-PEYROU, Sandra | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MONNEREAU, Alain | |
dc.contributor.author | BOISSARD, Frederic | |
dc.contributor.author | ROSSI, Cedric | |
dc.contributor.author | CAMUS, Vincent | |
dc.date.accessioned | 2023-12-07T14:15:25Z | |
dc.date.available | 2023-12-07T14:15:25Z | |
dc.date.issued | 2023-10-24 | |
dc.identifier.issn | 2473-9537 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/186443 | |
dc.description.abstractEn | Real-world data are essential to complement clinical trial (CT) data, but major challenges remain, like data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective non-interventional multicentric cohort started in 2018 (NCT03869619) including patients newly diagnosed with lymphoma in France. Herein is a proof-of-concept analysis on first-line DLBCL patients to (i) evaluate the capacity of the cohort to provide robust data through a multi-step validation process; (ii) assess the consistency of the results; (iii) conduct an exploratory transportability assessment of two recent phase 3 CT (POLARIX, SENIOR). The analysis population comprised DLBCL patients included before March 31st 2021, who received immunochemotherapy. 645 patients were included, for whom 3589 queries were generated, resulting in high data completeness (<4% missing data). Median age was 66 years (19-98) with mostly advanced-stage disease (472; 73%) and high international prognostic index (IPI) score (IPI 2-5, 486; 76%). Treatments were mostly R-CHOP (482; 75%) and R-miniCHOP (86; 13%). Estimated 1-year EFS and OS were 77.9% (95% CI: 73.8-81.4) and 90.0% (95% CI: 86.5-92.5), respectively (median follow-up: 9.9 months). Regarding transportability, when applying trials' main inclusion criteria (age, PS, IPI), outcomes seemed comparable between REALYSA patients and standard arms of POLARIX (1-year PFS 79.8% (95% CI, 75.9-83.6) vs. 79.8% (95% CI, 73.9-84.4)) and SENIOR (1-year EFS à 64.5% (95% CI: 47.8-77.0) vs. 60.0% (95% CI: 50.8-68.1)). With its rigorous data validation process, REALYSA program provides high-quality RWD, thus constituting a platform for numerous scientific purposes. | |
dc.language.iso | EN | en_US |
dc.subject.en | Diffuse large B-cell lymphoma | |
dc.subject.en | Real-world cohort data | |
dc.subject.en | REALYSA | |
dc.subject.en | Data quality | |
dc.subject.en | 75 clinical trial transportability | |
dc.title.en | Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort | |
dc.title.alternative | Blood Adv | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1182/bloodadvances.2023010798 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 37874913 | en_US |
bordeaux.journal | Blood Advances | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | EPICENE_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
bordeaux.identifier.funderID | Hospices Civils de Lyon | en_US |
bordeaux.identifier.funderID | Roche | en_US |
bordeaux.identifier.funderID | Takeda Oncology | en_US |
bordeaux.identifier.funderID | Janssen Pharmaceuticals | en_US |
bordeaux.identifier.funderID | Amgen | en_US |
bordeaux.identifier.funderID | Celgene | en_US |
bordeaux.identifier.funderID | F. Hoffmann-La Roche | en_US |
hal.identifier | hal-04329432 | |
hal.version | 1 | |
hal.date.transferred | 2023-12-07T14:15:30Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Blood%20Advances&rft.date=2023-10-24&rft.eissn=2473-9537&rft.issn=2473-9537&rft.au=GHESQUIERES,%20Herve&CHERBLANC,%20Fanny&BELOT,%20Aurelien&MICON,%20Sophie&BOUABDALLAH,%20Krimo&rft.genre=article |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |